MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'GSK news' source. Fri, 19 Mar 2010 16:14:30 +0100 http://www.medworm.com/index.php?rid=3381184&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10026.htm GSK announced that the first asthma patient has commenced treatment with Relovair™ (fluticasone furoate/vilanterol trifenatate) in an asthma exacerbation study, marking the start of the Phase III clinical development programme with this once daily therapy, for this serious and chronic disease. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3381184 Fri, 19 Mar 2010 09:00:00 +0100 3381184 http://www.medworm.com/index.php?rid=3368499&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10025.htm In its 2009 Corporate Responsibility Report published online today, GSK reiterated its commitment to running its business responsibly and to making the company more responsive, more flexible and more open to the expectations of society (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3368499 Tue, 16 Mar 2010 15:00:00 +0100 3368499 http://www.medworm.com/index.php?rid=3356880&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10023.htm GlaxoSmithKline (GSK) today announced management changes related to its Vaccines business as part of a planned succession strategy. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3356880 Fri, 12 Mar 2010 14:00:00 +0100 3356880 http://www.medworm.com/index.php?rid=3304806&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10021.htm Today, GlaxoSmithKline (GSK) responded to the recently released Senate Committee on Finance’s January 2010 “Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia” (the “Staff Report”) by releasing a White Paper. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3304806 Wed, 24 Feb 2010 14:30:00 +0100 3304806 http://www.medworm.com/index.php?rid=3293267&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10020.htm The Staff Report of the Senate Committee on Finance draws conclusions on the safety of Avandia (rosiglitazone) that are based on analyses that are not consistent with the rigorous scientific evidence supporting the safety of the drug. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3293267 Sat, 20 Feb 2010 21:00:00 +0100 3293267 http://www.medworm.com/index.php?rid=3293268&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10019.htm GlaxoSmithKline (GSK) rejects the conclusions about the safety of Avandia (rosiglitazone) reported in the February 20, 2010, New York Times story. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3293268 Sat, 20 Feb 2010 19:00:00 +0100 3293268 http://www.medworm.com/index.php?rid=3286092&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10018.htm GlaxoSmithKline (GSK) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued two positive opinions in the European Union for two of its cancer medicines. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3286092 Fri, 19 Feb 2010 11:15:00 +0100 3286092 http://www.medworm.com/index.php?rid=3286093&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10017.htm Because the safety and health of our consumers is our primary concern, GlaxoSmithKline (GSK) Consumer Healthcare is issuing a Consumer Advisory warning consumers about the potential health risks associated with long-term excessive use of zinc-containing denture adhesives. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3286093 Thu, 18 Feb 2010 17:00:00 +0100 3286093 http://www.medworm.com/index.php?rid=3281835&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_us_pressrelease_10013.htm GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™(gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3281835 Wed, 17 Feb 2010 02:15:00 +0100 3281835 http://www.medworm.com/index.php?rid=3238009&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Finvestors%2Fquarterly_results.htm GSK announces Q4 results 2009 (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3238009 Thu, 04 Feb 2010 12:00:00 +0100 3238009 http://www.medworm.com/index.php?rid=3226274&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10012.htm - Company progresses commitments to increase transparency (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3226274 Sat, 30 Jan 2010 02:00:00 +0100 3226274 http://www.medworm.com/index.php?rid=3214785&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10011.htm The New England Journal of Medicine (NEJM) today published the first study demonstrating that Rotarix™, GlaxoSmithKline’s rotavirus vaccine, significantly prevented severe rotavirus gastroenteritis during the first year of life in African babies. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3214785 Wed, 27 Jan 2010 22:00:00 +0100 3214785 http://www.medworm.com/index.php?rid=3341012&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10022.htm GSK CEO Andrew Witty today dedicated a new production facility at its Nashik site in India to the manufacture of albendazole, part of a combination treatment used within the World Health Organization’s Global Programme to Eliminate Lymphatic Filariasis. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3341012 Fri, 22 Jan 2010 10:30:00 +0100 3341012 http://www.medworm.com/index.php?rid=3196034&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10010.htm GlaxoSmithKline (GSK) and Genmab A/S announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Arzerraä (ofatumumab) for the treatment of refractory chronic lymphocytic leukaemia (CLL) (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3196034 Fri, 22 Jan 2010 10:30:00 +0100 3196034 http://www.medworm.com/index.php?rid=3187594&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10009.htm Andrew Witty, Chief Executive of GlaxoSmithKline, today announced a series of new initiatives targeted at further transforming the company’s approach to diseases that disproportionately affect the world’s poorest countries. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3187594 Wed, 20 Jan 2010 14:00:00 +0100 3187594 http://www.medworm.com/index.php?rid=3184205&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_us_pressrelease_10005.htm In keeping with GSK’s response to previous natural disasters, we have initiated a program of support for Haiti. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3184205 Mon, 18 Jan 2010 20:00:00 +0100 3184205 http://www.medworm.com/index.php?rid=3177804&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10006.htm Following declaration of the pandemic by the World Health Organization (WHO) in June 2009, GlaxoSmithKline (GSK) has been working closely with governments to respond to their changing needs as understanding of the H1N1 pandemic has increased. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3177804 Fri, 15 Jan 2010 15:00:00 +0100 3177804 http://www.medworm.com/index.php?rid=3158856&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2010%2F2010_pressrelease_10002.htm GlaxoSmithKline(GSK) andChemoCentryx Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialisation of Traficet-EN™ (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn’s disease (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3158856 Mon, 11 Jan 2010 13:00:00 +0100 3158856 http://www.medworm.com/index.php?rid=3098735&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10147.htm GlaxoSmithKline (GSK) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Revolade (eltrombopag), for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3098735 Fri, 18 Dec 2009 12:00:00 +0100 3098735 http://www.medworm.com/index.php?rid=3094714&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10146.htm - Next advance in the treatment of cold sores - Strengthens a key OTC franchise (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3094714 Wed, 16 Dec 2009 15:00:00 +0100 3094714 http://www.medworm.com/index.php?rid=3087716&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10145.htm - Company progresses commitments to increase transparency (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3087716 Mon, 14 Dec 2009 15:30:00 +0100 3087716 http://www.medworm.com/index.php?rid=3081421&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10144.htm In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3081421 Fri, 11 Dec 2009 18:30:00 +0100 3081421 http://www.medworm.com/index.php?rid=3081422&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10143.htm (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3081422 Fri, 11 Dec 2009 08:00:00 +0100 3081422 http://www.medworm.com/index.php?rid=3073766&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10142.htm GlaxoSmithKline (GSK) welcomes the introduction of a new measure – the ‘patent box’ – announced in the Pre-Budget Report to stimulate future investment in the UK. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3073766 Thu, 10 Dec 2009 13:00:00 +0100 3073766 http://www.medworm.com/index.php?rid=3069400&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10141.htm GlaxoSmithKline today announced initiation of the second large-scale Phase III clinical trial to evaluate long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome (ACS). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3069400 Wed, 09 Dec 2009 14:00:00 +0100 3069400 http://www.medworm.com/index.php?rid=3042513&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10140.htm GlaxoSmithKline (GSK) today announced that the World Health Organization (WHO) has awarded prequalification for global use of Arepanrix™, GSK’s adjuvanted H1N1 pandemic vaccine manufactured in Canada. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3042513 Tue, 01 Dec 2009 11:00:00 +0100 3042513 http://www.medworm.com/index.php?rid=3042514&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10139.htm GSK announced that yesterday it completed the extension of its strategic relationship with Aspen Pharmacare Holdings Limited (Aspen) and the acquisition of a minority shareholding in the South African based pharmaceuticals company. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3042514 Tue, 01 Dec 2009 10:00:00 +0100 3042514 http://www.medworm.com/index.php?rid=3038243&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10137.htm The London Organising Committee of the Olympic Games and Paralympic Games (LOCOG) today announces GlaxoSmithKline (GSK) as its Official Laboratory Services Provider in a Tier Three deal. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3038243 Mon, 30 Nov 2009 10:00:00 +0100 3038243 http://www.medworm.com/index.php?rid=3021380&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10135.htm GlaxoSmithKline (GSK) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced a licensing agreement to commercialise Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five countries in Asia. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3021380 Tue, 24 Nov 2009 14:00:00 +0100 3021380 http://www.medworm.com/index.php?rid=3018045&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10134.htm GSK announced today that in order to provide an update to the application, the company is withdrawing its US sNDA for Avodart® (dutasteride) for prostate cancer risk reduction among men at increased risk of developing the disease. GSK expects to resubmit the file shortly. This action is not the result of new findings related to safety or efficacy. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3018045 Mon, 23 Nov 2009 14:00:00 +0100 3018045 http://www.medworm.com/index.php?rid=3018046&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10133.htm GlaxoSmithKline (GSK) today announced that over 40 million doses of its adjuvanted pandemic H1N1 vaccine have been distributed to countries globally for use in government-initiated vaccination programmes. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=3018046 Mon, 23 Nov 2009 10:15:00 +0100 3018046 http://www.medworm.com/index.php?rid=2994776&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10130.htm - Upfront and potential consideration of over $500 million (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2994776 Mon, 16 Nov 2009 11:00:00 +0100 2994776 http://www.medworm.com/index.php?rid=2979571&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10129.htm GlaxoSmithKline (GSK) today announced that the US Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for its unadjuvanted influenza A (H1N1) pandemic vaccine. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2979571 Tue, 10 Nov 2009 23:00:00 +0100 2979571 http://www.medworm.com/index.php?rid=2975930&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10128.htm GlaxoSmithKline (GSK) today announced that it has signed an agreement with the World Health Organization (WHO) to donate 50 million doses of its adjuvanted pandemic H1N1 influenza vaccine to WHO for distribution to developing countries most in need. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2975930 Tue, 10 Nov 2009 08:00:00 +0100 2975930 http://www.medworm.com/index.php?rid=2975931&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_us_pressrelease_10081.htm GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2975931 Mon, 09 Nov 2009 14:45:00 +0100 2975931 http://www.medworm.com/index.php?rid=2972848&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10127.htm GlaxoSmithKline (GSK) today announced the results from the clinical trial assessing Pandemrix™, GSK’s adjuvanted H1N1 pandemic influenza vaccine, administered at the same time as the annual seasonal influenza vaccine, Fluarix ®. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2972848 Mon, 09 Nov 2009 09:30:00 +0100 2972848 http://www.medworm.com/index.php?rid=2969257&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10126.htm Endorsement is first for vaccine for pneumococcal disease - a life-threatening disease affecting many children; follows first-ever World Pneumonia Day (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2969257 Fri, 06 Nov 2009 15:30:00 +0100 2969257 http://www.medworm.com/index.php?rid=2953087&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10123.htm Dr Dominique Limet, CEO of ViiV Healthcare, promises 'relentless pursuit' of new treatments (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2953087 Tue, 03 Nov 2009 08:00:00 +0100 2953087 http://www.medworm.com/index.php?rid=2949520&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10122.htm GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International (VRX) announced today that, on 30 October, they filed a New Drug Application with the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMEA), for retigabine, used as adjunctive therapy to treat adult epilepsy patients with partial-onset seizures (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2949520 Mon, 02 Nov 2009 13:00:00 +0100 2949520 http://www.medworm.com/index.php?rid=2949521&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10121.htm - Benlysta (belimumab) 10 mg/kg plus standard of care met its primary efficacy endpoint by achieving a statistically significant improvement in patient response rate versus placebo plus standard of care at Week 52 in BLISS-76 - Primary efficacy endpoint met in two pivotal Phase 3 trials, as specified by Special Protocol Assessment agreement with FDA (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2949521 Mon, 02 Nov 2009 08:45:00 +0100 2949521 http://www.medworm.com/index.php?rid=2933212&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Finvestors%2Fquarterly_results.htm GlaxoSmithKline plc (GSK) announced third quarter results for 2009 (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2933212 Wed, 28 Oct 2009 12:00:00 +0100 2933212 http://www.medworm.com/index.php?rid=2929538&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10119.htm GlaxoSmithKline (GSK) today announced that this week, approximately half a million people will have received its pandemic H1N1 vaccine, Pandemrix™, as part of Government initiated vaccination programmes across Europe, which commenced earlier this month (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2929538 Tue, 27 Oct 2009 14:00:00 +0100 2929538 http://www.medworm.com/index.php?rid=2929539&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10117.htm GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the first patient has commenced treatment as part of the Phase III programme being undertaken to develop a next-generation combination treatment for patients with chronic obstructive pulmonary disorder (COPD), a leading cause of chronic illness and death. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2929539 Tue, 27 Oct 2009 12:00:00 +0100 2929539 http://www.medworm.com/index.php?rid=2929540&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_us_pressrelease_10077.htm GSK and Genmab announced the accelerated approval of ArzerraTM (ofatumumab) from the US Food and Drug Administration for use in patients with chronic lymphocytic leukemia (CLL) that is refractory to fludarabine and alemtuzumab. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2929540 Mon, 26 Oct 2009 23:59:59 +0100 2929540 http://www.medworm.com/index.php?rid=2918454&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10116.htm GlaxoSmithKline (GSK) today announced that, to date, more than 150,000 people have received GSK's pandemic H1N1 vaccine, Pandemrix™, as part of Government initiated vaccination programmes across Europe which commenced last week. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2918454 Fri, 23 Oct 2009 13:00:00 +0100 2918454 http://www.medworm.com/index.php?rid=2907239&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10115.htm BENLYSTA (belimumab) significantly reduced SLE disease activity, disease flare rates and fatigue; significantly delayed time-to-first SLE disease flare; reduced prednisone use and improved health-related patient quality of life in the BLISS-52 study (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2907239 Tue, 20 Oct 2009 10:30:00 +0100 2907239 http://www.medworm.com/index.php?rid=2897149&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10111.htm GlaxoSmithKline (GSK) today announced results from a second clinical trial of its pandemic (H1N1) adjuvanted vaccine, which demonstrate that one dose of the vaccine can provide a strong immune response which exceeds criteria as defined by international licensing authorities using the lowest dose of antigen available in pandemic vaccines. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2897149 Fri, 16 Oct 2009 13:56:30 +0100 2897149 http://www.medworm.com/index.php?rid=2897150&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10110.htm Landmark approval paves the way for access to the vaccine for women in Japan. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2897150 Fri, 16 Oct 2009 11:00:00 +0100 2897150 http://www.medworm.com/index.php?rid=2888838&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10109.htm GlaxoSmithKline (GSK) and Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics, today announced that they have entered into an exclusive worldwide collaboration for the development and commercialisation of RNA based therapeutics for Duchenne Muscular Dystrophy (DMD) (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2888838 Tue, 13 Oct 2009 16:00:00 +0100 2888838 http://www.medworm.com/index.php?rid=2885050&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10108.htm GlaxoSmithKline plc (GSK) announced today that it has entered into a unique partnership with the UK Government, The Wellcome Trust and the East of England Development Agency (EEDA) to develop an innovative new biotechnology science park located at GSK’s site at Stevenage. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2885050 Tue, 13 Oct 2009 10:30:00 +0100 2885050 http://www.medworm.com/index.php?rid=2885051&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10197.htm GlaxoSmithKline (GSK) announced today that final results from a large, 4-year study showed that Avodart (dutasteride) and tamsulosin combination treatment reduced the risk of acute urinary retention (AUR) or Benign Prostatic Hyperplasia* (BPH)-related surgery and reduced the risk of BPH clinical progression more than tamsulosin alone (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2885051 Mon, 12 Oct 2009 15:00:00 +0100 2885051 http://www.medworm.com/index.php?rid=2864441&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10105.htm GlaxoSmithKline (GSK) and Jiangsu Walvax Biotech Company (Walvax) today announced a cooperation agreement to form a long-term Joint Venture (JV) to develop and manufacture paediatric vaccines for use in China. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2864441 Tue, 06 Oct 2009 09:00:00 +0100 2864441 http://www.medworm.com/index.php?rid=2864442&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10104.htm GSK is committed to supporting governments and health authorities around the world respond to the pandemic (H1N1) 2009 influenza strain. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2864442 Tue, 06 Oct 2009 07:00:00 +0100 2864442 http://www.medworm.com/index.php?rid=2864443&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10103.htm GlaxoSmithKline today announced that the United States Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT™ (pazopanib). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2864443 Mon, 05 Oct 2009 21:00:00 +0100 2864443 http://www.medworm.com/index.php?rid=2844792&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10094.htm GlaxoSmithKline (GSK) confirmed today that the European Commission has granted marketing authorisation of GSK’s pandemic (H1N1) adjuvanted vaccine Pandemrix™ for protection against pandemic H1N1 2009 influenza. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2844792 Wed, 30 Sep 2009 11:45:00 +0100 2844792 http://www.medworm.com/index.php?rid=2837770&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_us_pressrelease_10091.htm GlaxoSmithKline (GSK) today announced an exclusive agreement with President (Shanghai) Trading Co. Ltd, a wholly-owned trading arm of Uni-President China Holdings Ltd (UPCH), one of the leading food and beverage companies in China, to launch GSK's highly successful Lucozade drinks franchise across China (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2837770 Mon, 28 Sep 2009 17:23:54 +0100 2837770 http://www.medworm.com/index.php?rid=2837771&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10090.htm GlaxoSmithKline (GSK) has made the difficult decision to discontinue the regulatory filings for Zunrisa/Rezonic (casopitant), which was being developed for chemotherapy-induced and post-operative nausea and vomiting. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2837771 Mon, 28 Sep 2009 10:30:00 +0100 2837771 http://www.medworm.com/index.php?rid=2830696&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10089.htm GlaxoSmithKline (GSK) announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion and recommends approval of GSK’s candidate pandemic (H1N1) adjuvanted vaccine Pandemrix™. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2830696 Fri, 25 Sep 2009 10:00:00 +0100 2830696 http://www.medworm.com/index.php?rid=2792121&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10087.htm GlaxoSmithKline (GSK) today announced results from its first clinical trial assessing use of its pandemic (H1N1) adjuvanted vaccine. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2792121 Mon, 14 Sep 2009 12:00:00 +0100 2792121 http://www.medworm.com/index.php?rid=2780640&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_us_pressrelease_10056.htm GlaxoSmithKline announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that clinical data support both the efficacy and safety of CERVARIX®, the company’s candidate cervical cancer vaccine (12-1 and 11-1, respectively). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2780640 Wed, 09 Sep 2009 18:45:00 +0100 2780640 http://www.medworm.com/index.php?rid=2707201&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10085.htm GlaxoSmithKline plc (GSK) announced today that it has launched a unique partnership with Brazil’s Oswaldo Cruz Foundation (Fiocruz) to develop and manufacture vaccines for pressing public health priorities in Brazil. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2707201 Mon, 17 Aug 2009 15:00:00 +0100 2707201 http://www.medworm.com/index.php?rid=2701247&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10084.htm GSK today issued an update on its progress to develop a vaccine against the Pandemic (H1N1) 2009 influenza virus, and announced that it has commenced the clinical development programme for its adjuvanted pandemic vaccine. Enrolment into this first study has been completed. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2701247 Fri, 14 Aug 2009 13:00:00 +0100 2701247 http://www.medworm.com/index.php?rid=2669504&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10081.htm GSK is committed to supporting governments and health authorities around the world respond to the pandemic (H1N1) 2009 influenza strain. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2669504 Tue, 04 Aug 2009 17:00:00 +0100 2669504 http://www.medworm.com/index.php?rid=2652176&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_us_pressrelease_10047.htm GSK and Genmab A/S announced today preliminary top-line results from a Phase III study of ofatumumab administered intravenously for the treatment of rheumatoid arthritis (RA) in patients who had an inadequate response to methotrexate. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2652176 Wed, 29 Jul 2009 21:00:00 +0100 2652176 http://www.medworm.com/index.php?rid=2647556&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10079.htm GSK today announced that it has notified the European Medicines Agency of its decision to withdraw the Marketing Authorisation Application (MAA) in the EU for mepolizumab for the treatment of hypereosinophilic syndrome (HES). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2647556 Wed, 29 Jul 2009 11:00:00 +0100 2647556 http://www.medworm.com/index.php?rid=2669505&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_us_pressrelease_10046.htm Amgen to retain full rights for denosumab in the United States and Canada and for oncology indications in Europe. GlaxoSmithKline will commercialize denosumab for PMO and oncology in Emerging Markets. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2669505 Mon, 27 Jul 2009 21:00:00 +0100 2669505 http://www.medworm.com/index.php?rid=2628577&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10078.htm GlaxoSmithKline plc (GSK) today announced that it has completed its acquisition of Stiefel Laboratories, Inc. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2628577 Wed, 22 Jul 2009 15:30:00 +0100 2628577 http://www.medworm.com/index.php?rid=2628578&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10077.htm GlaxoSmithKline (GSK) today issued an update on its progress to support governments and health authorities around the world respond to pandemic (H1N1) 2009 influenza. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2628578 Wed, 22 Jul 2009 13:00:00 +0100 2628578 http://www.medworm.com/index.php?rid=2624105&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Finvestors%2Fquarterly_results.htm Results announcement for Q2 2009 (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2624105 Wed, 22 Jul 2009 11:30:05 +0100 2624105 http://www.medworm.com/index.php?rid=2624106&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10075.htm GlaxoSmithKline (GSK) and Enigma Diagnostics Limited today announced that they have signed worldwide agreements to develop and supply the first point-of-care diagnostic influenza tests to identify specific influenza virus strains using its real-time Polymerase Chain Reaction (PCR) technology platform, the Enigma ML (Mini Laboratory). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2624106 Tue, 21 Jul 2009 12:00:00 +0100 2624106 http://www.medworm.com/index.php?rid=2616271&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10074.htm Human Genome Sciences, Inc. and GSK today announced that Benlysta™ (belimumab, formerly LymphoStat-B®) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2616271 Mon, 20 Jul 2009 10:30:00 +0100 2616271 http://www.medworm.com/index.php?rid=2600109&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10073.htm Andrew Witty, Chief Executive Officer of GlaxoSmithKline, today announced a series of new initiatives targeted at improving research, development, and access to HIV/AIDS medicines for children in Sub-Saharan Africa and supporting healthcare for people living with HIV and AIDS. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2600109 Tue, 14 Jul 2009 11:30:00 +0100 2600109 http://www.medworm.com/index.php?rid=2582591&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10072.htm The WHO decision is necessary for UN agencies and the GAVI Alliance to purchase the vaccine in partnership with developing countries and will help speed access to Cervarix globally. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2582591 Thu, 09 Jul 2009 10:30:00 +0100 2582591 http://www.medworm.com/index.php?rid=2582592&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10071.htm GSK and Alnylam Pharmaceuticals, Inc. announced today that Alnylam will contribute more than 1500 issued or pending patents on its RNAi technology patent estate to the patent pool established by GSK earlier this year. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2582592 Wed, 08 Jul 2009 13:00:00 +0100 2582592 http://www.medworm.com/index.php?rid=2575011&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10070.htm Largest efficacy trial of a cervical cancer vaccine showed Cervarix® protects against the five most common cancer-causing virus types (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2575011 Tue, 07 Jul 2009 00:00:01 +0100 2575011 http://www.medworm.com/index.php?rid=2566748&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10069.htm GSK today announced that it has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m (£14.2m). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2566748 Thu, 02 Jul 2009 09:00:00 +0100 2566748 http://www.medworm.com/index.php?rid=2519614&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10068.htm GlaxoSmithKline (GSK) today announced that the Commercial Court in Dublin, Ireland, ruled in patent litigation regarding GSK’s product Seretide, an inhaled respiratory treatment for asthma and COPD. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2519614 Fri, 26 Jun 2009 14:30:00 +0100 2519614 http://www.medworm.com/index.php?rid=2494200&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_us_pressrelease_10042.htm GlaxoSmithKline confirmed today that it has received a complete response letterfrom the FDA related to the application for casopitant. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2494200 Tue, 23 Jun 2009 16:15:00 +0100 2494200 http://www.medworm.com/index.php?rid=2481895&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10065.htm GlaxoSmithKline and Genmab A/S today announced that the United States Food and Drug Administration (FDA) informed the companies that the agency has extended the action date for the ofatumumab BLA application by three months. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2481895 Tue, 16 Jun 2009 11:15:00 +0100 2481895 http://www.medworm.com/index.php?rid=2494201&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10067.htm GlaxoSmithKline (LSE: GSK) and Chroma Therapeutics Limited announced today a collaboration to develop macrophage-targeted compounds using Chroma’s proprietary esterase-sensitive motif (ESM) technology, which adds amino acid esters to compounds with the aim of targeting the compounds to specific cells in the inflammatory disease process. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2494201 Tue, 16 Jun 2009 10:15:00 +0100 2494201 http://www.medworm.com/index.php?rid=2481896&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10064.htm GlaxoSmithKline plc (GSK) today announced an agreement with Dr. Reddy’s Laboratories Ltd (Dr. Reddy’s) to develop and market selected products across an extensive number of emerging markets, excluding India. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2481896 Mon, 15 Jun 2009 12:45:00 +0100 2481896 http://www.medworm.com/index.php?rid=2481897&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10063.htm The World Health Organisation (WHO) has announced it has raised the current level of influenza pandemic alert from phase 5 to phase 6. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2481897 Fri, 12 Jun 2009 10:30:00 +0100 2481897 http://www.medworm.com/index.php?rid=2466368&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10061.htm GSK today announced it has entered into a definitive agreement to form a new Joint Venture with Shenzhen Neptunus focused on developing and manufacturing influenza vaccines for the Chinese market. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2466368 Tue, 09 Jun 2009 07:00:00 +0100 2466368 http://www.medworm.com/index.php?rid=2466369&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10060.htm New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria® (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2466369 Sun, 07 Jun 2009 14:00:00 +0100 2466369 http://www.medworm.com/index.php?rid=2461401&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10059.htm RECORD trial also demonstrates durable blood sugar control over time with Avandia (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2461401 Fri, 05 Jun 2009 21:15:00 +0100 2461401 http://www.medworm.com/index.php?rid=2461402&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10058.htm The World Health Organisation (WHO) has awarded global prequalification to GlaxoSmithKline Biologicals’ vaccine against rotavirus, Rotarix™. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2461402 Fri, 05 Jun 2009 15:00:00 +0100 2461402 http://www.medworm.com/index.php?rid=2461403&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10057.htm GSK and Concert Pharmaceuticals announced today that they will collaborate to develop and commercialise deuterium-containing medicines. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2461403 Tue, 02 Jun 2009 21:00:00 +0100 2461403 http://www.medworm.com/index.php?rid=2450987&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_us_pressrelease_10039.htm Today, GlaxoSmithKline announced the results of a Phase III study demonstrating that pazopanib reduced the risk of tumor progression or death by 54 percent compared to placebo. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2450987 Mon, 01 Jun 2009 15:45:00 +0100 2450987 http://www.medworm.com/index.php?rid=2450988&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_us_pressrelease_10037.htm GSK and Genmab A/S announced that the US FDA ODAC voted 10 to three that the Arzerra™ (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2450988 Fri, 29 May 2009 20:00:00 +0100 2450988 http://www.medworm.com/index.php?rid=2435209&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10055.htm GSK announced today that the US Department of Health and Human Services (HHS) has placed initial orders for A (H1N1) influenza vaccine antigen and the company’s proprietary adjuvant system, AS03, to support its pandemic influenza preparation efforts. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2435209 Fri, 22 May 2009 22:00:00 +0100 2435209 http://www.medworm.com/index.php?rid=2409819&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10054.htm GSK is committed to supporting governments and health authorities around the world to respond to the emergence of the new A (H1N1) influenza strain. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2409819 Fri, 15 May 2009 11:30:00 +0100 2409819 http://www.medworm.com/index.php?rid=2409820&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10052.htm GlaxoSmithKline plc (GSK) today announced that it has agreed to extend its strategic relationship with Aspen Pharmacare Holdings Limited (Aspen) and to acquire a 16% shareholding in the South African based pharmaceuticals company. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2409820 Tue, 12 May 2009 08:15:00 +0100 2409820 http://www.medworm.com/index.php?rid=2401182&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10051.htm Key results from three important studies of the cervical cancer vaccine, Cervarix®, will be available as of today at the 25th International Papillomavirus Conference (IPV) in Malmö, Sweden. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2401182 Fri, 08 May 2009 07:00:00 +0100 2401182 http://www.medworm.com/index.php?rid=2394372&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10049.htm GSK today announced that it has entered into an agreement to divest full commercial rights to Wellbutrin XL® in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation, for $510 million (£340 million). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2394372 Wed, 06 May 2009 07:00:00 +0100 2394372 http://www.medworm.com/index.php?rid=2385057&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10048.htm GlaxoSmithKline (GSK) is committed to supporting governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2385057 Fri, 01 May 2009 17:00:00 +0100 2385057 http://www.medworm.com/index.php?rid=2372031&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10047.htm Primary endpoint achieved in REDUCE study as presented at American Urological Association (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2372031 Mon, 27 Apr 2009 16:50:00 +0100 2372031 http://www.medworm.com/index.php?rid=2372032&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10046.htm GlaxoSmithKline (GSK) is closely monitoring the situation regarding the emergence of a new influenza A (H1N1) strain in Mexico, the United States of America, Canada, France, Spain and New Zealand. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2372032 Mon, 27 Apr 2009 14:00:00 +0100 2372032 http://www.medworm.com/index.php?rid=2355537&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Finvestors%2Fquarterly_results.htm GSK delivers Q1 EPS of 26.3p before major restructuring and increased dividend of 14p (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2355537 Wed, 22 Apr 2009 12:00:00 +0100 2355537 http://www.medworm.com/index.php?rid=2344586&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10044.htm GSK has today announced that alli – the first clinically proven over the counter weight loss aid – is available in pharmacies across Europe. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2344586 Mon, 20 Apr 2009 13:00:00 +0100 2344586 http://www.medworm.com/index.php?rid=2344587&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10042.htm GlaxoSmithKline plc (GSK) and Stiefel Laboratories Inc. today announced that they have signed an agreement to create a new world-leading specialist dermatology business. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2344587 Mon, 20 Apr 2009 08:00:00 +0100 2344587 http://www.medworm.com/index.php?rid=2336308&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10041.htm GlaxoSmithKline plc (GSK) and Pfizer Inc (PFE) today announced they have entered into an agreement to create a new world-leading HIV company focused solely on research, development and commercialisation of HIV medicines. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2336308 Thu, 16 Apr 2009 11:00:00 +0100 2336308 http://www.medworm.com/index.php?rid=2313892&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10040.htm GlaxoSmithKline (GSK) today announced the submission of two simultaneous regulatory applications to expand the use of Tyverb®/Tykerb® (lapatinib). If authorised, lapatinib could be used as a first-line therapy regimen combined with anti-hormonal therapy for patients with hormone-sensitive, metastatic (or advanced) breast cancer in Europe and the United States. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2313892 Wed, 01 Apr 2009 14:00:00 +0100 2313892 http://www.medworm.com/index.php?rid=2313893&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10039.htm GlaxoSmithKline (GSK) today received European Commission authorisation for Synflorix™, a paediatric pneumococcal vaccine to protect against life-threatening diseases such as meningitis and bacteraemic pneumonia, as well as middle ear infections. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2313893 Tue, 31 Mar 2009 15:00:00 +0100 2313893 http://www.medworm.com/index.php?rid=2313894&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10038.htm GlaxoSmithKline submits final study data to FDA for cervical cancer vaccine (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2313894 Mon, 30 Mar 2009 14:00:00 +0100 2313894 http://www.medworm.com/index.php?rid=2313895&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10036.htm In its Corporate Responsibility Report published today, GSK reiterated its commitment to running its business responsibly and transparently. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2313895 Tue, 24 Mar 2009 13:00:00 +0100 2313895 http://www.medworm.com/index.php?rid=2279612&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10035.htm GlaxoSmithKline plc (the “Group”) announces today that it has sold 5,749,157 shares of common stock, par value of $0.01 per share (the “Shares”), of Quest Diagnostics Inc. (“Quest”). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2279612 Thu, 19 Mar 2009 21:00:00 +0100 2279612 http://www.medworm.com/index.php?rid=2236254&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10031.htm GSK reiterates commitment to 12 week free access programme (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2236254 Thu, 05 Mar 2009 10:45:00 +0100 2236254 http://www.medworm.com/index.php?rid=2236255&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10030.htm GlaxoSmithKline (GSK) today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for pazopanib as an oral therapy for patients with advanced and/or metastatic renal cell carcinoma (RCC). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2236255 Wed, 04 Mar 2009 15:45:00 +0100 2236255 http://www.medworm.com/index.php?rid=2192542&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10025.htm GlaxoSmithKline today announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria® (albiglutide) in men and women with type 2 diabetes. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2192542 Tue, 17 Feb 2009 14:00:00 +0100 2192542 http://www.medworm.com/index.php?rid=2164690&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10024.htm GlaxoSmithKline and Idenix Pharmaceuticals, Inc.today announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2164690 Fri, 06 Feb 2009 12:15:00 +0100 2164690 http://www.medworm.com/index.php?rid=2164691&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10023.htm GlaxoSmithKline and Genmab A/S announced today the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for Arzerra™ (ofatumumab) for the treatment of chronic lymphocytic leukaemia (CLL). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2164691 Thu, 05 Feb 2009 18:30:00 +0100 2164691 http://www.medworm.com/index.php?rid=2161504&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10022.htm GSK delivers EPS of 104.7p before major restructuring. Dividend increased 8% to 57p (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2161504 Thu, 05 Feb 2009 12:00:00 +0100 2161504 http://www.medworm.com/index.php?rid=2158108&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10021.htm - Data increase confidence in the Horizon development programme (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2158108 Wed, 04 Feb 2009 13:00:00 +0100 2158108 http://www.medworm.com/index.php?rid=2151135&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10019.htm GlaxoSmithKline plc announces that Mr. James Murdoch has been appointed as a Non-Executive Director and will join the Board of the Company with effect from 20th May 2009. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2151135 Mon, 02 Feb 2009 15:15:00 +0100 2151135 http://www.medworm.com/index.php?rid=2145443&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10018.htm GlaxoSmithKline and Genmab A/S announced today the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Arzerra™(ofatumumab) to treat patients whose chronic lymphocytic leukaemia (CLL) is resistant (refractory) to previous therapies. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2145443 Fri, 30 Jan 2009 16:00:00 +0100 2145443 http://www.medworm.com/index.php?rid=2145444&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10017.htm GSK today announced that Deirdre Connelly will join the company as President, North American Pharmaceuticals, effective Monday 9 February 2009. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2145444 Fri, 30 Jan 2009 13:00:00 +0100 2145444 http://www.medworm.com/index.php?rid=2142600&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10015.htm - The UK is now one of the world’s leading countries in stockpiling antivirals for treating infected individuals in the event of an influenza pandemic (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2142600 Thu, 29 Jan 2009 20:49:18 +0100 2142600 http://www.medworm.com/index.php?rid=2142599&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10016.htm GSK today announced that it will record a legal charge in the fourth quarter of 2008 of $400 million (£278 million) relating to an ongoing investigation initiated by the US Attorney’s Office in Colorado into the Group’s US marketing and promotional practices for several products for the period 1997 to 2004. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2142599 Thu, 29 Jan 2009 14:10:00 +0100 2142599 http://www.medworm.com/index.php?rid=2126551&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10014.htm GlaxoSmithKline plc (GSK) today announced that it has signed an agreement with UCB S.A to acquire its current marketed product portfolio across certain territories in Africa, the Middle East, Asia Pacific and Latin America, for a cash consideration of €515 million (£483 million.) (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2126551 Fri, 23 Jan 2009 06:00:00 +0100 2126551 http://www.medworm.com/index.php?rid=2126552&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10012.htm Serotypes included in the vaccine are responsible for up to 90% of invasive pneumoccal disease in young children in Europe. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2126552 Thu, 22 Jan 2009 18:30:00 +0100 2126552 http://www.medworm.com/index.php?rid=2123215&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10011.htm A decision made by the European Commission today opens access to a treatment that could help people who are overweight and obese. GSK has received a non-prescription licence for alli (orlistat 60mg); the first time the European Commission has approved a non-prescription product for weight loss. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2123215 Wed, 21 Jan 2009 13:00:00 +0100 2123215 http://www.medworm.com/index.php?rid=2090907&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2009_pressrelease_10007.htm GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the NDA to the U.S. FDA requesting approval of Solzira™ Extended Release Tablets for the treatment of moderate-to-severe primary RLS. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2090907 Fri, 09 Jan 2009 13:30:00 +0100 2090907 http://www.medworm.com/index.php?rid=2085085&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2009%2F2008_pressrelease_10152.htm GlaxoSmithKline plc announced today the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares of common stock of Genelabs Technologies, Inc. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2085085 Wed, 07 Jan 2009 14:00:00 +0100 2085085 http://www.medworm.com/index.php?rid=2063309&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10151.htm GlaxoSmithKline and Cytokinetics, Incorporated announced today that GSK has informed Cytokinetics that it will not exercise its option to license ispinesib or SB-743921 as provided under the Collaboration and License Agreement entered into by the companies in 2001. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2063309 Tue, 23 Dec 2008 21:15:00 +0100 2063309 http://www.medworm.com/index.php?rid=2063310&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_us_pressrelease_10149.htm GlaxoSmithKline and Archemix Corp. today announced a worldwide strategic alliance to discover, develop and commercialise aptamer therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2063310 Tue, 23 Dec 2008 08:15:00 +0100 2063310 http://www.medworm.com/index.php?rid=2056771&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10148.htm GlaxoSmithKline today announced a new global policy to voluntarily stop all corporate political contributions. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2056771 Mon, 22 Dec 2008 14:00:00 +0100 2056771 http://www.medworm.com/index.php?rid=2056772&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10147.htm GlaxoSmithKline Plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from the Phase 2b study of the novel, long-acting beta agonist (LABA) GW642444 (‘444) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2056772 Mon, 22 Dec 2008 13:00:00 +0100 2056772 http://www.medworm.com/index.php?rid=2056773&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10146.htm GlaxoSmithKline (GSK) announced today that it has entered into a definitive agreement through which GSK will acquire Bristol-Myers Squibb Pakistan (Private) Ltd. (BMSP) and certain associated trademarks for approximately $36.5 million (£24.6 million). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2056773 Mon, 22 Dec 2008 12:00:00 +0100 2056773 http://www.medworm.com/index.php?rid=2048933&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10144.htm GlaxoSmithKline today announced initiation of the first pivotal Phase III clinical trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2048933 Thu, 18 Dec 2008 13:00:00 +0100 2048933 http://www.medworm.com/index.php?rid=2043392&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_us_pressrelease_10143.htm Developing first-in-class endosomal TLR inhibitors for autoimmune and inflammatory diseases (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2043392 Wed, 17 Dec 2008 11:30:00 +0100 2043392 http://www.medworm.com/index.php?rid=2034622&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10140.htm GFindings from one of the largest studies in hormone receptor positive women determined clinical benefit with first-line oral treatment regimen (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2034622 Sat, 13 Dec 2008 18:49:54 +0100 2034622 http://www.medworm.com/index.php?rid=2034621&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10141.htm The following is GlaxoSmithKline’s [NYSE: GSK] statement regarding recommendations of a combined Advisory Committee to the FDA on the use of asthma medicines containing long-acting beta agonists, including GSK’s Serevent® (salmeterol) and Seretide/Advair® (fluticasone propionate and salmeterol). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2034621 Sat, 13 Dec 2008 18:49:54 +0100 2034621 http://www.medworm.com/index.php?rid=2036259&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10142.htm Up to 1,000 UK companies able to follow pharmaceutical giant’s sustainable lead. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2036259 Fri, 12 Dec 2008 00:01:00 +0100 2036259 http://www.medworm.com/index.php?rid=2022900&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10139.htm Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who have failed standard treatments (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2022900 Mon, 08 Dec 2008 21:00:00 +0100 2022900 http://www.medworm.com/index.php?rid=2022901&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_us_pressrelease_10168.htm Data in infants and young children reinforce case for phase III trial of RTS,S/AS (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2022901 Mon, 08 Dec 2008 17:30:00 +0100 2022901 http://www.medworm.com/index.php?rid=2022902&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10137.htm GlaxoSmithKline announced that it has extended its previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2022902 Mon, 08 Dec 2008 14:00:00 +0100 2022902 http://www.medworm.com/index.php?rid=2022903&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10135.htm Patients who received eltrombopag over six months were eight times more likely to generate sustained elevated platelet counts than patients who received placebo. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2022903 Sat, 06 Dec 2008 17:00:00 +0100 2022903 http://www.medworm.com/index.php?rid=2019480&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10136.htm The U.S. Food and Drug Administration today posted a comprehensive review conducted by GlaxoSmithKline of its clinical and observational data that demonstrated better overall asthma control with the combination medicine Seretide/Advair (fluticasone propionate and salmeterol) than with a single medicine alone. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2019480 Fri, 05 Dec 2008 15:00:00 +0100 2019480 http://www.medworm.com/index.php?rid=2019481&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_us_pressrelease_10160.htm GSK CEO marks 10th anniversary of drive to eliminate lymphatic filariasis (LF) with donation of one-billionth albendazole tablet and grant to The Carter Center. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2019481 Fri, 05 Dec 2008 00:00:01 +0100 2019481 http://www.medworm.com/index.php?rid=2019482&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_us_pressrelease_10158.htm GlaxoSmithKline announced today that it is waiving a condition relating to a pending lawsuit in the previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc., for $1.30 per share in cash without interest and less any required withholding taxes. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2019482 Wed, 03 Dec 2008 21:30:00 +0100 2019482 http://www.medworm.com/index.php?rid=2008456&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10134.htm tial results demonstrate potential of `444 in the treatment of patients with moderate to severe asthma (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=2008456 Tue, 02 Dec 2008 13:00:00 +0100 2008456 http://www.medworm.com/index.php?rid=1977525&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10133.htm GlaxoSmithKline (GSK) today announced that it has signed an exclusive Cooperation Agreement with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT) (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=1977525 Fri, 21 Nov 2008 10:00:00 +0100 1977525 http://www.medworm.com/index.php?rid=1977526&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10127.htm GlaxoSmithKline today announced that the United States Food and Drug Administration (FDA) granted accelerated approval for Promacta® (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=1977526 Thu, 20 Nov 2008 22:45:00 +0100 1977526 http://www.medworm.com/index.php?rid=1977527&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10124.htm GlaxoSmithKline (GSK) today announced that it has entered into an agreement with AstraZeneca to acquire a number of leading over-the-counter (OTC) medicines predominantly sold in Sweden, including Alvedon. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=1977527 Thu, 20 Nov 2008 14:30:00 +0100 1977527 http://www.medworm.com/index.php?rid=1977528&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10123.htm GlaxoSmithKline’s (GSK) cervical cancer vaccine, CervarixTM, was today confirmed by the Netherlands Vaccine Institute (NVI) as the cervical cancer vaccine for the Dutch National Immunisation Programme (NIP). (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=1977528 Thu, 20 Nov 2008 09:00:00 +0100 1977528 http://www.medworm.com/index.php?rid=1953397&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10121.htm GlaxoSmithKline announced today that Gemstone Acquisition Corporation, a wholly-owned subsidiary of GSK, is commencing a cash tender offer to purchase all outstanding shares of common stock of Genelabs Technologies, Inc., for $1.30 in cash without interest and less any required withholding taxes. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=1953397 Wed, 12 Nov 2008 14:30:00 +0100 1953397 http://www.medworm.com/index.php?rid=1953398&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10120.htm Following the conclusion of a recent review of activities at GSK’s manufacturing site in Dartford, it is proposed that the facility be closed and production be transferred to alternative facilities. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=1953398 Tue, 11 Nov 2008 17:00:00 +0100 1953398 http://www.medworm.com/index.php?rid=1948635&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_pressrelease_10119.htm GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that the New Drug Application (NDA) for Solzira™ (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) has been withdrawn. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=1948635 Mon, 10 Nov 2008 14:00:00 +0100 1948635 http://www.medworm.com/index.php?rid=1918770&cid=s_37964_34_f&fid=37964&url=http%3A%2F%2Fwww.gsk.com%2Fmedia%2Fpressreleases%2F2008%2F2008_us_pressrelease_10145.htm GlaxoSmithKline and Genelabs Technologies, Inc. announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (£35 million) through a tender offer of $1.30 per share in cash. (Source: GSK news) GSK news organizations http://www.medworm.com/rss/comments.php?id=1918770 Wed, 29 Oct 2008 01:00:00 +0100 1918770